Prognostic biomarkers in colorectal cancer: where do we stand?
about
Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patientsGenetic variations in genes of metabolic enzymes predict postoperational prognosis of patients with colorectal cancer.Telomeres and telomerase in the clinical management of colorectal cancer.Grading lymph node metastasis: a feasible approach for prognostication of patients with stage III colorectal cancer.Overexpression of c-Myb is associated with suppression of distant metastases in colorectal carcinoma.
P2860
Prognostic biomarkers in colorectal cancer: where do we stand?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Prognostic biomarkers in colorectal cancer: where do we stand?
@en
type
label
Prognostic biomarkers in colorectal cancer: where do we stand?
@en
prefLabel
Prognostic biomarkers in colorectal cancer: where do we stand?
@en
P2860
P1433
P1476
Prognostic biomarkers in colorectal cancer: where do we stand?
@en
P2093
Xavier Sagaert
P2860
P2888
P304
P356
10.1007/S00428-013-1532-Z
P577
2014-02-01T00:00:00Z